+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06260033

Phase II Study of Stereotactic Body Radiation Therapy and FES PETCT Imaging in Patients with Limited Progression of Estrogen Receptor Positive Metastatic Breast Cancer

Led by City of Hope Medical Center · Updated on 2026-10-07

18

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating stereotactic body radiation therapy SBRT for patients with estrogen receptor positive ER metastatic breast cancer that has spread to a limited number of sites, known as oligoprogression. This phase II trial aims to determine if SBRT can help patients continue their current systemic therapy for at least 24 weeks after treatment. Additionally, the study assesses the use of ER-targeted positron emission tomographycomputed tomography FES PETCT imaging to better identify progressive disease in these patients. Participants who are currently on selective estrogen receptor modulators SERMs or degraders SERDs receive 3 or 5 fractions of SBRT within three weeks, provided they have no unacceptable toxicity or more than four progressing disease sites. Those not on SERMsSERDs first undergo intravenous FES administration followed by PETCT scans before receiving SBRT if they have up to four progressing sites. FES PETCT scans are repeated at 12 and 24 weeks, with additional SBRT offered if progression remains limited. Screening includes CT, PETCT, or bone scans and blood sample collection. During the study, participants complete quality of life questionnaires and are monitored for adverse events using standard criteria and patient-reported outcomes. Blood samples are collected to study tumor DNA over time. Follow-up occurs 30 days after study treatments, and researchers measure how long patients remain on their systemic therapy, progression-free survival, and changes in the number of lesions detected by imaging. The total participation duration includes up to 24 weeks post-treatment monitoring.

CONDITIONS

Brief Title

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here